Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00280397
Status:
COMPLETED
Last Update Posted:
2016-10-07
First Post:
2006-01-20
Brief Title:
An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
Status:
COMPLETED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the maximum tolerable dose MTD and the related effects of E7080 administered to patients with solid tumors that are resistant to approved existing anti-tumor therapies or for which no appropriate treatment is available
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None